Neuropathology of Parkinson’s disease after focused ultrasound thalamotomy

Shunsuke Koga1, Mariam Ishaque2, W. Jeffrey Elias3, Binit B. Shah2, Aya Murakami1 and Dennis W. Dickson1✉

Focused ultrasound (FUS) thalamotomy is an emerging treatment for tremor-dominant Parkinson’s disease (PD). We report the first postmortem neuropathologic study of FUS thalamotomy in a 68-year-old man with tremor-dominant PD, which was performed seven months before he died. Although the peak voxel temperature at the target was <54 °C, his tremor improved on intraoperative and postoperative assessments. Additionally, postoperative MRI demonstrated a thalamic lesion. Lewy body-related pathology consistent with PD was detected. There was also a 5-mm lesion in the ventral lateral thalamus characterized by demyelination and neuropil loss, with many lipid-laden macrophages, but no lymphocytic infiltrates and relatively preserved neurons and axons. Additional pathological assessments after FUS thalamotomy are needed to determine if the observed brain changes are typical of this procedure.

npj Parkinson’s Disease (2022) 8:59; https://doi.org/10.1038/s41531-022-00319-6

INTRODUCTION

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder characterized by bradykinesia, rigidity, postural instability, and tremor at rest. Dopamine replacement therapy is the gold standard treatment for PD, but there is a subset of tremor-dominant PD patients for whom medical therapy does not achieve successful tremor control. Deep brain stimulation (DBS) targeting the subthalamic nucleus, globus pallidus interna and ventral intermediate nucleus of the thalamus has become widely used. DBS requires an open cranial procedure for device implantation, which is associated with the risk of hemorrhagic and infectious complications.

Magnetic resonance (MR)-guided focused ultrasound (FUS) is an incision-free procedure for precise thermal ablation of deep structures in the brain. Clinical trials of FUS thalamotomy targeting the ventral intermediate nucleus of the thalamus in patients with refractory essential tremor have shown safety and efficacy. This led to approval of this treatment by the United States Food and Drug Administration (FDA) in 2016–8. Subsequently, FUS thalamotomy was approved in 2018 by the FDA for tremor-dominant PD intolerant or refractory to dopamine replacement therapy. Very recently, FUS pallidotomy was also approved for treatment of dyskinesia in PD. Longitudinal changes in lesions after FUS treatment have been investigated with MRI, which show changes consistent with necrosis in the center of the lesion and cytotoxic and vasogenic edema in the periphery. Histopathological correlates of these lesions have not been reported in humans, only in experimental animals. We report the first postmortem neuropathological findings of a PD patient who underwent FUS thalamotomy.

RESULTS

Case report

The patient was a 68-year-old Caucasian right-handed man with a 12-year history of tremor-dominant PD. His symptoms started with a left foot tremor at 56 years of age. By age 67, the tremor was bilateral, and it impaired activities of daily living. Carbidopa/levodopa (400–700 mg/day) suppressed his tremors but produced severe dyskinesias. On neurological examination, he had bradykinesia and bilateral tremor, most severe in the left lower and right upper extremities. Additional symptoms included falls and daytime visual hallucinations. Neurocognitive testing showed no cognitive impairment.

His right hand tremor was the most bothersome symptom and was not optimally controlled with medications. He was a candidate for either DBS implantation or a clinical trial of FUS subthalamotomy. After the discussion of the merits and limitations of each procedure, he opted for FUS subthalamotomy as he perceived it to be less invasive. He underwent a screening head CT scan, which showed a favorable skull density ratio (SDR; a ratio of cortical to cancellous bone) of 0.55, but also revealed a right intracranial mass. Thus, he was excluded from the FUS subthalamotomy clinical trial. Further workup indicated malignant choroidal melanoma with metastases to the liver (stage IV). He underwent right eye enucleation and adjuvant chemotherapy. After the treatment for his melanoma, he underwent a left FUS thalamotomy procedure to control disabling right upper extremity tremor.

Intraoperative SDR was 0.51. He demonstrated improved intra- and postoperative tremor control without any adverse events. An MRI of the brain on postoperative day 1 demonstrated an expected thalamic lesion with surrounding edema, restricted diffusion and intralesional blood products (Fig. 1). Two months after the thalamotomy, he was hospitalized with progressive tetraparesis and paresthesias while undergoing immunotherapy treatment for his melanoma. He died at home on hospice care 7 months after FUS thalamotomy.

MR-guided FUS treatment characteristics

The patient received eleven transcranial sonications. The first five sonications were significantly modulated to avoid acoustic cavitation (i.e., the collapse of bubbles); however, cavitation was observed during the alignment phase. To mitigate this, the multi...
echo imaging was turned off, and additional no-pass regions were designated to the membrane folds. The water bath was drained and refilled, and the tissue type was changed for the sensitivity of the cavitation detectors. Three alignment sonications were then performed, requiring 6700 J of energy for a mild temperature rise at the focus. This ensured that the natural focus of the transducer matched the two-dimensional plane of thermal imaging. Finally, three therapeutic sonications delivered acoustic energies of 16,000, 24,000, and 36,000 J. The peak voxel temperatures at the target only reached 51–54 °C, but the sonication durations were prolonged (20–35 s), and the tremor was gone in both resting and postural phases.

**Pathological findings**

The fixed left hemibrain weighed 600 g. Macroscopic findings revealed no significant cortical atrophy and no enlargement of frontal or temporal horns of the lateral ventricle. The hippocampus, amygdala, basal ganglia, and subthalamic nucleus were unremarkable. The substantia nigra (Fig. 2a) and locus coeruleus had decreased neuromelanin pigment. Haematoxylin and eosin (H&E) stains showed severe neuronal loss with gliosis and extracellular pigment, as well as Lewy bodies (arrows) in the remaining neurons in the substantia nigra (Fig. 2b). Immunohistochemistry for α-synuclein revealed abundant Lewy bodies and Lewy neurites (Fig. 2c), consistent with the neuropathological diagnosis of PD17.

A 5-mm × 3-mm lesion was observed in the ventral lateral thalamus at the level of the mammillothalamic tract (arrow in Fig. 2d). The lesion was characterized by many foamy macrophages, immunoreactive for CD68 and less for IBA-1, but relatively preserved neurons compared to the adjacent thalamus (Fig. 2e–o). There was myelin loss and a few myelin figures in the macrophages with Luxol fast blue-periodate-Schiff (LFB-PAS) stain (Fig. 2i). There were reactive astrocytes throughout the thalamus, but GFAP immunoreactivity was decreased in the macrophage-rich region (Fig. 2p, q). Immunohistochemistry for phosphorylated neurofilament (SMI-31) showed relatively preserved axons, and non-phosphorylated neurofilament (SMI-32) showed relatively preserved neuronal populations in this lesion (Fig. 2r–u). There were no axonal

**Fig. 1** Representative MRI on postoperative day 1. a T1-weighted image shows hypointense lesion in the thalamus. b T2-weighted image shows hyperintense lesion with a small hypointense core. c Diffusion-weighted image demonstrates diffusion restriction within the lesion, suggesting tissue infarction. d Susceptibility-weighted image demonstrates hypointense blood products within the lesion.
swellings on amyloid precursor protein (APP) immunohistochemistry. Immunohistochemistry for CD3 (Fig. 2v, w), CD45RO and CD20 revealed no significant infiltration of T cells or B cells in the lesion or adjacent tissue. No infarction or hemorrhage was observed. Additional neuropathologic findings included sparse neurofibrillary tangles in the entorhinal cortex, but no senile plaques consistent with primary age-related tauopathy (Braak neurofibrillary tangle stage II; Thal amyloid phase 0).
The lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. a-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra. d A lesion related to FUS thalamotomy is visible in the ventral lateral thalamus at the level of the mammillothalamic tract. e-m Lower magnification of the thalamus on hematoxylin and eosin (H&E) stains (e), Luxol fast blue-periodate-Schiff stain (LFB-PAS) stains (f), and immunohistochemistry for α-synuclein (NACP antibody) reveals Lewy bodies (arrows) and Lewy neurites in the substantia nigra. The remaining neurons contain Lewy bodies (arrows) and Lewy neurites in the substantia nigra.
increasing energy. Clinical monitoring of the patient was obtained after each sonication. Tremor was assessed in the resting and postural states as well as with finger-to-nose and drawing tasks. Potential neurologic adverse effects were monitored with sensory and motor testing, and there were none.

Neuropathological assessment
The left hemibrain was fixed in formalin and standardized sections were embedded in paraffin. Regions sampled for histopathological assessment included six regions of the neocortex, two levels of the hippocampus, a basal forebrain section that includes the amygdala, lentiform nucleus and hypothalamus, anterior corpus striatum, thalamus at the level of the subthalamic nucleus, midbrain,pons, medulla, and two sections of the cerebellum, one including the deep nuclei. Paraffin-embedded 5-µm-thick sections mounted on glass slides were stained with H&E and thioflavin S (Sigma-Aldrich, St. Louis, MO). Braak neurofibrillary tangle stage and Thal amyloid phase were assessed with thioflavin S fluorescent microscopy according to published criteria, as previously described. Sections of the cortex, hippocampus, and basal forebrain, and brainstem were immunostained with anti-α-synuclein antibody (NACP; rabbit polyclonal; 1:3000; Mayo Clinic Antibody; formic acid pretreatment) using IHC Autostainer 4805 (Thermo Fisher Scientific Inc., Waltham, MA) and DAKO EnVision™ reagents (Dako, Carpinteria, CA) to confirm a diagnosis of PD. To characterize the lesion related to FUS, we also performed LFB-embedded 5-µm-thick sections mounted on glass slides stained with H&E and thioflavin S. PAS stains and immunohistochemistry for activated microglia (CD68; Leica, Wetzlar, Germany) and astrocytes (GFAP; GA-5; mouse monoclonal; 1:5000; BioGenex, Fremont, CA), phosphorylated neurofilaments (SMI-31; mouse monoclonal; 1:20,000; Ultraclone, Berkeley, CA), and non-phosphorylated neurofilaments (SMI-32; mouse monoclonal; 1:1000; BioLegend, San Diego, CA), amylod precursor protein (APP; mouse monoclonal; 1:1000; Millipore Sigma, Burlington, MA), T-cells (CD3; mouse monoclonal; 1:100; Dako), memory T-cells (CD45/CD69; mouse monoclonal; 1:1000, Dako), and B-cells (CD20; mouse monoclonal; 1:1000; Dako) using the section including the thalamus.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
Research data are not publicly available since it is protected health information.

Received: 13 December 2021; Accepted: 17 February 2022;
Published online: 12 May 2022

REFERENCES
1. Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
2. Lozano, A. M. et al. Deep brain stimulation: current challenges and future directions. Nat. Rev. Neurol. 15, 148–160 (2019).
3. Patel, D. M. et al. Adverse events associated with deep brain stimulation for movement disorders: analysis of 510 consecutive cases. Neurosurgery 11(Suppl. 2), 190–199 (2015).
4. Lachenmeyer, M. L. et al. Subthalamic and pallidal deep brain stimulation for Parkinson’s disease-meta-analysis of outcomes. NPJ Parkinsons Dis. 7, 77 (2021).
5. Meng, Y., Hynynen, K. & Lipsman, N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat. Rev. Neurol. 17, 7–22 (2021).
6. Elias, W. J. et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 369, 640–648 (2013).
7. Park, Y. S., Jiang, N. Y., Na, Y. C. & Chang, J. W. Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov. Disord. 34, 727–734 (2019).
8. Elias, W. J. et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 375, 730–739 (2016).
9. Bond, A. E. et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant parkinson disease: a randomized clinical trial. JAMA Neurol. 74, 1412–1418 (2017).
10. Eisenberg, H. M. et al. MR-guided focused ultrasound pallidotomy for Parkinson’s disease: safety and feasibility. J. Neurosurg. 1–7 https://doi.org/10.3171/2020.6. JNS192773 (2020).
11. Wintervale, M. et al. Imaging findings in MR imaging-guided focused ultrasound treatment for patients with essential tremor. Am. J. Neuroradiol. 35, 891–896 (2014).
12. Harary, M., Essayed, W. I., Valdes, P. A., McDonnell, N. & Cosgrove, G. R. Volumetric analysis of magnetic resonance-guided focused ultrasound thalamotomy lesions. Neurosurg. Focus 44, E6 (2018).
13. Elias, W. J. et al. A magnetic resonance imaging, histological, and dose modeling comparison of focused ultrasound, radiofrequency, and Gamma Knife radiosurgery lesions in swine thalamus. J. Neurosurg. 119, 307–317 (2013).
14. Xu, Z. et al. Intracranial inertial cavitation threshold and thermal ablation lesion creation using MRI-guided 220-kHz focused ultrasound surgery: preclinical investigation. J. Neurosurg. 122, 152–161 (2015).
15. Walker, M. R. et al. Acute MR-guided high-intensity focused ultrasound lesion assessment using diffusion-weighted imaging and histological analysis. Front. Neurol. 10, 1069 (2019).
16. Martinez-Fernandez, R. et al. Randomized trial of focused ultrasound subthalamotomy for Parkinson’s disease. N. Engl. J. Med. 383, 2501–2513 (2020).
17. Dickson, D. W. et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157 (2009).
18. Jung, N. Y. et al. The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson’s disease: a Phase I clinical trial. J. Neurosurg. 1–9 https://doi.org/10.3171/2018.3.JNS172514 (2018).
19. Yang, A. I. et al. Patient-specific effects on sonication heating efficiency during magnetic resonance-guided focused ultrasound thalamotomy. Med. Phys. 48, 6588–6596 (2021).
20. Wilson, D. N., Barnett, Y., Kyle, K., Tisch, S. & Jonker, B. P. Predictors of thermal response and lesion size in patients undergoing magnetic resonance-guided focused ultrasound thalamotomy. J. Clin. Neurosci. 91, 75–79 (2021).
21. Chang, W. S. et al. Factors associated with successful magnetic resonance-guided focused ultrasound treatment: efficiency of acoustic energy delivery through the skull. J. Neurosurg. 124, 411–416 (2016).
22. Kim, M. J. et al. Technical and operative factors affecting magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor: experience from 250 treatments. J. Neurosurg. 1–9 https://doi.org/10.3171/2020.11. JNS2002580 (2021).
23. Weng, T. R. et al. Transcranial magnetic resonance imaging-guided focused ultrasound thalamotomy for tremor: technical note. Neurosurg. Focus 44, E3 (2018).
24. Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
25. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
26. Montine, T. J. et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 123, 1–11 (2012).
27. Koga, S., Zhou, X. & Dickson, D. W. Machine learning based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. Neuropathol. Appl. Neurobiol. https://doi.org/10.1111/nan.12710 (2021).
28. Dickson, D. W. et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241–1251 (1999).

ACKNOWLEDGEMENTS
The authors would like to acknowledge Virginia Phillips, Aристон Liberо, and Jo A. Landino García (Mayo Clinic) for histologic support, and Monica Canastenes-Casey (Mayo Clinic) for immunohistochemistry support. This work is supported by CurePSP, the Rainwater Charitable Trust, and the Jaye F. and Betty F. Dyer Foundation Fellowship in progressive supranuclear palsy research.

AUTHOR CONTRIBUTIONS
S.K. and D.W.D. designed this study and performed the pathological assessment. S.K. wrote the manuscript with significant input from M.L., W.E., and B.B.S. W.E., and B.B.S. contributed to the clinical assessment and FUS procedure of the patient.
A.M. contributed to the interpretation of the pathological assessment. All authors critically revised the draft and approved the final version.

COMPETING INTERESTS
S.K., M.I., B.B.S., A.M., and D.W.D. declare no competing interests. W.J.E. serves as a consultant for InSightec LTD.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41531-022-00319-6.

Correspondence and requests for materials should be addressed to Dennis W. Dickson.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022